These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 18322437

  • 1. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S.
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
    [No Abstract] [Full Text] [Related]

  • 2. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR.
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [Abstract] [Full Text] [Related]

  • 3. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T.
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [Abstract] [Full Text] [Related]

  • 4. Have we forgotten the purpose of phase III studies?
    Flynn JM, Byrd JC.
    J Clin Oncol; 2007 Dec 10; 25(35):5553-5. PubMed ID: 17984184
    [No Abstract] [Full Text] [Related]

  • 5. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
    Nabhan C.
    Clin Lymphoma Myeloma; 2005 Sep 10; 6(2):115-21. PubMed ID: 16231849
    [Abstract] [Full Text] [Related]

  • 6. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I, Grossbard ML.
    Clin Lymphoma; 2004 Mar 10; 4(4):228-9. PubMed ID: 15072614
    [No Abstract] [Full Text] [Related]

  • 7. Alemtuzumab in chronic lymphocytic leukemia.
    James DF, Kipps TJ.
    Future Oncol; 2007 Feb 10; 3(1):29-42. PubMed ID: 17280499
    [Abstract] [Full Text] [Related]

  • 8. Alemtuzumab in CLL and other lymphoid neoplasms.
    Ravandi F, O'brien S.
    Cancer Invest; 2006 Nov 10; 24(7):718-25. PubMed ID: 17118783
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
    O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ.
    Cancer; 2003 Dec 15; 98(12):2657-63. PubMed ID: 14669286
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 15; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 11. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M, Schinkoethe T, Elter T.
    Cancer Invest; 2005 Jul 15; 23(6):488-96. PubMed ID: 16203656
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
    Boyd K, Dearden CE.
    Expert Rev Anticancer Ther; 2008 Apr 15; 8(4):525-33. PubMed ID: 18402519
    [Abstract] [Full Text] [Related]

  • 13. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ.
    Expert Rev Anticancer Ther; 2002 Feb 15; 2(1):23-35. PubMed ID: 12113063
    [Abstract] [Full Text] [Related]

  • 14. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
    Rai KR.
    Haematologica; 1999 Jun 15; 84 Suppl EHA-4():94-5. PubMed ID: 10907481
    [No Abstract] [Full Text] [Related]

  • 15. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.
    J Clin Oncol; 2006 May 20; 24(15):2337-42. PubMed ID: 16618945
    [Abstract] [Full Text] [Related]

  • 16. Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.
    Laurenti L, Tarnani M, Innocenti I, Savino G, Battendieri R, Larocca LM, Chiusolo P, Sorà F, Sica S, Efremov D, Leone G.
    J Clin Oncol; 2008 Nov 10; 26(32):5299-301. PubMed ID: 18854557
    [No Abstract] [Full Text] [Related]

  • 17. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T.
    Expert Rev Anticancer Ther; 2008 Jul 10; 8(7):1033-51. PubMed ID: 18588450
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
    Grey M.
    Br J Haematol; 2008 Jul 10; 142(1):1. PubMed ID: 18477054
    [No Abstract] [Full Text] [Related]

  • 19. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS, Abou Jawde RM.
    J Clin Oncol; 2008 Dec 10; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract] [Full Text] [Related]

  • 20. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
    Stilgenbauer S, Döhner H.
    N Engl J Med; 2002 Aug 08; 347(6):452-3. PubMed ID: 12167696
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.